- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
Bullish outlook for Eli Lilly due to strong sales momentum and durable patent coverage for its obesity treatment portfolio into the 2030s.
1 report, 1 independent
Updated Jul 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bullish outlook for Eli Lilly due to strong sales momentum and durable patent coverage for its obesity treatment portfolio into the 2030s.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.Also in this story
- Novo Nordisk and Eli Lilly are utilizing physician networks in Texas, including Carlos Campos, to promote their weight-loss drugs.
- Eli Lilly's clinical trial results showed their pill was less effective than Wegovy, leading to market discussion among analysts and market watchers like Mizuho.
- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
- Teva obtained FDA approval for a generic drug, challenging Novo Nordisk's market share in the GLP-1RA space.
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Eli Lilly and Kailera Therapeutics are competing in the obesity treatment market.
- Eli Lilly and Company has achieved market leadership in the obesity and diabetes treatments sector.
- The FDA is ending compounding grace periods as competition intensifies and Lilly faces pipeline setbacks in the GLP-1 market.
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
Coverage
Newest first; wire copies grouped- GuruFocus.comWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth July 11 -Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its